TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07729995: BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease

Sponsor: Luminary Therapeutics · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 94 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT07729995 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07729995 Rescue Dossier →